Pregabalin

Amber-G

Brand Name(s):Lyrica

Indication:Anticonvulsant

Rationale:

Considered:Sep-06

Review Date:Mar-26

Comments:
Updated guidance MHRA February ’21:

*pregabalin has been associated with reports of respiratory depression, in some cases without concomitant opioid treatment
*consider whether adjustments in dose or dosing regimen are necessary for patients at higher risk of respiratory depression, this includes people: *with compromised respiratory function, respiratory or neurological disease, or renal impairment
*taking other CNS depressants (including opioid-containing medicines)
*aged older than 65 years

SPC update – sections 4.4 and 4.5 advise caution when used with opioids due to risk of CNS depression – this increased risk was observed at low doses of pregabalin (? 300 mg) and there was a trend for a greater risk at high doses of pregabalin.

Drug Safety Update
Antiepileptic drugs: updated advice on switching between different manufacturers’ products
Nov 2017
…………………………
NICE CG137
Feb2016
Drug Safety Update available at:http://www.mhra.gov.uk/safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-A-F/Antiepilepticschangingproducts/index.htm

Drug Safety Update December 2012